A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE

Clinical trial NCT07118241 · RECRUITING

Trial details

NCT number: NCT07118241
Sponsor: Lubris Bio Pty Ltd
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Sjögren's Syndrome

Start date: 2025-09-17
Primary completion: 2026-07-30
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.